Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

164383

	registered interest
	date	24/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans NHS England has to consult (a) charities and (b) patients after the Cancer Drugs Fund panel meets on 15 and 16 December 2014 and before decisions on which drugs remain on the Cancer Drugs Fund list are made public.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	215694
	answer	answer is ministerial correction date of answer 01/12/2014 answer text <p>NHS England’s Cancer Drugs Fund panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p>NHS England has advised that a meeting will be held with representatives of charities and patient groups on 12 January 2015 to communicate the outcome of the panel’s discussion, clarify the process by which decisions were made and the rationale for these.</p><p> </p><p>This meeting will form part of the two month notice period prior to any drugs being formally removed from the national Cancer Drugs Fund list.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 215687 question first answered 01/12/2014 17:07:34 answering member 4020 label Biography information for George Freeman
	tabling member	4025 label Biography information for Mrs Pauline Latham

174027

	registered interest
	date	15/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans NHS England has to respond to patient groups and charities who are concerned about the removal of clinically effective drugs from the Cancer Drugs Fund.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	220954
	answer	answer is ministerial correction date of answer 21/01/2015 answer text <p>NHS England has advised that a meeting with patient groups and charities was held on 19 January 2015 to provide the context for the changes being made to the national Cancer Drugs Fund (CDF) list, how the review was undertaken by the CDF clinical panel and the results. Attendees had the opportunity to ask questions to provide further clarity.</p><p> </p><p> </p><p> </p><p>Information on the outcomes from the review is available on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf" target="_blank">www.england.nhs.uk/ourwork/pe/cdf</a></p><p> </p><p> </p><p> </p><p>and has been circulated to NHS England networks. Clinicians are also being informed via the regional CDF teams.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 220955 question first answered 21/01/2015 16:01:35 answering member 4020 label Biography information for George Freeman
	tabling member	4025 label Biography information for Mrs Pauline Latham

174028

	registered interest
	date	15/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps NHS England plans to take to ensure that patients and clinicians are aware of the drugs delisted from the Cancer Drugs Fund as announced on 12 January 2015.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	220955
	answer	answer is ministerial correction date of answer 21/01/2015 answer text <p>NHS England has advised that a meeting with patient groups and charities was held on 19 January 2015 to provide the context for the changes being made to the national Cancer Drugs Fund (CDF) list, how the review was undertaken by the CDF clinical panel and the results. Attendees had the opportunity to ask questions to provide further clarity.</p><p> </p><p> </p><p> </p><p>Information on the outcomes from the review is available on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf" target="_blank">www.england.nhs.uk/ourwork/pe/cdf</a></p><p> </p><p> </p><p> </p><p>and has been circulated to NHS England networks. Clinicians are also being informed via the regional CDF teams.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 220954 question first answered 21/01/2015 16:01:35 answering member 4020 label Biography information for George Freeman
	tabling member	4025 label Biography information for Mrs Pauline Latham

391814

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure access for NHS patients to innovative new medicines that have received marketing authorisation before their assessment from NICE.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	8316
	answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>In the absence of guidance from the National Institute for Health and Care Excellence, it is for commissioners to make decisions on whether to fund new medicines based on an assessment of the available evidence.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/09/2015 12:17:10 answering member 4020 label Biography information for George Freeman
	tabling member	4025 label Biography information for Mrs Pauline Latham

391817

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nivolumab
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions he has had on the availability of nivolumab for melanoma patients through the Cancer Drugs Fund.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	8315
	answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>We have had no such discussions.</p><p> </p><p> </p><p> </p><p>NHS England is responsible for the operational management of the Cancer Drugs Fund. It has taken a decision not to consider new drugs like nivolumab, at this stage, whilst consideration is given to new ways of working and to ensure that the Fund remains within budget.</p><p> </p><p> </p><p> </p><p>We understand that NHS England and the National Institute for Health and Care Excellence will shortly be consulting jointly on a proposed new system for commissioning cancer drugs.</p><p> </p><p> </p><p> </p><p>The Government remains committed to the Fund which has so far helped over 72,000 people in England access the cancer drugs their doctors recommend for them.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/09/2015 14:48:52 answering member 4020 label Biography information for George Freeman
	tabling member	4025 label Biography information for Mrs Pauline Latham

417686

	registered interest
	date	08/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of patient access to innovative drugs approved under the MHRA's Early Access to Medicines Scheme ahead of NICE assessments and in the absence of any planned Cancer Drugs Fund meetings.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	9598
	answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The Early Access to Medicines Scheme (EAMS) was launched in April 2014. Its purpose is to support access in the United Kingdom to unlicensed or off-label medicines representing a significant advance in treatment in areas of unmet medical need.</p><p> </p><p> </p><p> </p><p>EAMS is a 2 step process. First, the Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency (MHRA) is designed to give an early signal that based on early clinical evidence the medicine may be a possible candidate for EAMS and thus have the potential to be of value in areas of unmet medical need. There have been eight EAMS Promising Innovative Medicines designations issued so far.</p><p> </p><p> </p><p> </p><p>Second, the EAMS scientific opinion by the MHRA, which we envisage will usually be towards the end of the development process, enables prescribers and patients to decide if the EAMS medicine might be suitable for that individual patient. Four positive EAMS scientific opinions have been issued.</p><p> </p><p> </p><p> </p><p>For medicines granted a scientific opinion and which then receive a marketing authorisation, it is for commissioners to make funding decisions in advance of any technology appraisal guidance from the National Institute for Health and Care Excellence.</p><p> </p><p> </p><p> </p><p>There will be a review of EAMS as part of the Accelerated Access Review currently underway.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 12:28:34 answering member 4020 label Biography information for George Freeman
	tabling member	4025 label Biography information for Mrs Pauline Latham